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risk. During follow-up, increases in Ishak stage, hepatic collagen, and
ELF were associated with progression to cirrhosis. Changes in NAS
were not significant, but worsening lobular inflammation was
associated with increased progression (HR 3.21; 95% CI 1.14, 9.04).
After a median of 26.7months (range, 0.1–42.3), 49 cirrhotic subjects
(19.0%) experienced clinical events (ascites [n = 19], encephalopathy
[n = 13], variceal hemorrhage [n = 6], newly-diagnosed varices [n = 4],
≥2-point increase in Child-Pugh score and/or MELD≥ 15 [n = 6],
death [n = 1]). Factors associated with disease progression included
higher BL hepatic collagen and ELF, increases in these markers over
time, and lack of improvement in Ishak stage (Table). Changes in NAS
were not significant although the absence of improved lobular
inflammation was associated with increased risk (HR 2.33; 95% CI
1.01–5.35).
Table: Factors Associated with Disease Progression in Patients with
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Baseline 4 vs. 3
















































Baseline ≤ 2 vs. 3–4






















*Changes from baseline adjusted for baseline value.
1Combined no change or worsening as reference group for subjects with
cirrhosis (Ishak stage 5 or 6) at baseline because cirrhotic subjects with Ishak
stage 6 fibrosis cannot have an increase in fibrosis stage.
2No subjectswith bridging fibrosis at baselinewho had Ishak improvement had
a clinical event.
3No subjects with bridging fibrosis and a NAS≤ 2 at baseline had a clinical
event.
Conclusions: In patients with advanced fibrosis due to NASH, the
primary determinant of disease progression is fibrosis and its change
over time.
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Background and Aims: Treatment of common bile duct disorders
such as biliary atresia is limited to liver transplantation or
hepatojejunostomy due to the lack of suitable tissue for surgical
reconstruction. Here we explore the potential of bioengineered
biliary tissue consisting of human extrahepatic cholangiocyte
organoids (ECOs) and biodegradable scaffolds for biliary reconstruc-
tion in vivo.
Methods: Primary human cholangiocytes were isolated by mechan-
ical dissociation from deceased organ donors with ethical approval
and informed consent (n = 8). Propagation of ECOs was achieved
using our established protocol. Transcriptomic characterization was
performed using the Illumina HumanHT-12v4 array. ECOs were
seeded on Polyglycolic Acid (PGA) or densified collagen scaffolds.
Biliary reconstruction was achieved by partially replacing the
gallbladder wall with an ECO populated PGA-scaffold patch (ECO-
patch; n = 8), or replacing a length of the native common bile duct
with ECO populated collagen tubes (ECO-tubes) through end-to-end
anastomosis (n = 4). All experiments were performed in immune
compromisedmice. Fibroblast-populated (n = 5, PGA; n = 4, collagen)
or acellular scaffolds (n = 2, PGA) were used as negative controls.
Biliary tree patency was confirmed using magnetic resonance
cholangiopancreatography (MRCP) or cholangiogram.
Results: ECOs closely correlatewith primary cholangiocytes in terms
of transcriptomic profile (r:0.92), and functional properties (ALP, GGT,
bile acid transfer). ECO-populated scaffolds form biliary tissue-
resembling structures, maintain their functional properties (ALP,
GGT) and marker expression (CK7, CK19, HNF1B). All ECO-trans-
planted animals exhibited prolonged survival (ECO-patch vs. acellu-
lar controls, P = 0.0027; ECO-tubes vs. fibroblasts, P = 0.0082; log-rank
test). The transplanted cells integrated in the biliary epithelium,
continued expressing biliary markers (CK7, CK19, HNF1B), exhibited
ALP activity and a patent lumen. All reconstructions with fibroblasts
failed, the biliary epithelium was replaced by fibrotic tissue and the
lumen of the gallbladder or neo-bile duct was occluded.
Conclusions: We demonstrate that ECO-populated biodegradable
scaffolds maintain key biliary characteristics and can reconstruct/
replace parts of the biliary tree following transplantation. To our
knowledge, this is the first demonstration for the application of
regenerative medicine in the management of cholangiopathies and
first report of an organ reconstruction using human primary cells
expanded in vitro.
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